PEREBRON ® Oxolamina

PEREBRON ® is a drug based on Oxolamine citrate or Oxolamine phosphate

THERAPEUTIC GROUP: Cough sedatives

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications PEREBRON ® Oxolamina

PEREBRON ® is indicated for the symptomatic treatment of cough.

Mechanism of action PEREBRON ® Oxolamina

PEREBRON ® is a drug based on Oxolamine, an active ingredient that mainly has an anti-inflammatory and antitussive action, therefore useful in the course of inflammatory diseases of the respiratory tract marked by persistent cough.

Taken orally it is quickly absorbed by the gastrointestinal tract and immediately distributed in a circle, through which it reaches the respiratory system with high affinity, where it carries out its therapeutic action.

In fact, by controlling the on-site inflammatory microenvironment, it reduces the degree of activation and irritation of the C fibers assigned to the somatosensory sensitivity coming from the respiratory tree and the alveolar region, thus limiting the onset of the reflex at the base of the cough.

The local and non-central anti-cough action, obviously also limits the potential central side effects, classically associated with cough sedatives such as codeine derivatives.

Once the activity is completed, within 24 hours, the active ingredient and its catabolites are all eliminated via the kidneys.

Studies carried out and clinical efficacy

HALLUCINATIONS BY OXOLAMINA

Med J Aust. 1989 Apr 17; 150 (8): 449-50, 452.

Case report that reports the appearance of side effects and in particular neuropsychiatric symptoms such as hallucinations, in a young patient receiving Oxolamine citrate.

PHARMACOGENOMICS AND PHARMACOLOGICAL INTERACTIONS

Biopharm Drug Dispos. 2007 Apr; 28 (3): 125-33.

Innovative work that evaluates the role of genetic predisposition, and in particular of polymorphisms of cytochromial enzymes, in determining pharmacologically relevant interactions between oral anticoagulants and oxolamine.

RELEASE METHODS OF? ™ OXOLAMINE

J Microencapsul. 1992 Apr-Jun; 9 (2): 167-72.

Pharmacokinetic study oriented to the molecular characterization of the pharmacokinetic properties of? ™ Oxalamina and to the identification of new release methods, able to optimize the therapeutic activity of the drug

Method of use and dosage

PEREBRON ®

Oxolamine citrate 100 mg coated tablets;

Syrup for adults of 1.4 g of Oxolamine phosphate per 100 ml of product;

Syrup for children of 1 g of Oxolamine citrate per 100 ml of product;

Oral drops of 8 g of Oxolamine citrate per 100 ml of product;

Suppositories for adults from 500 mg of Oxolamina citrate;

Suppositories for children from 250 mg of Oxolamine citrate.

Dosage and timing of intake related to PEREBRON ® should be defined by your doctor based on the chosen pharmaceutical format, the general characteristics of the patient and the severity of your clinical picture.

It is recommended to take PEREBRON ® on a full stomach.

Warnings PEREBRON ® Oxolamina

The use of PEREBRON ® should be preceded by an appropriate medical consultation, aimed at clarifying the causes of the complained symptomatology and the possible presence of potential contraindications.

It is also advisable to remember that this treatment is symptomatic, therefore useful to limit the symptoms without solving the basic therapy.

PEREBRON ® in syrup contains sucrose, therefore it is not very suitable for patients suffering from saccharase enzyme deficiency, fructose intolerance and glucose-galactose malabsorption.

It is advisable to store the drug out of reach of children and in a cool, dry place.

PREGNANCY AND BREASTFEEDING

The absence of studies able to better characterize the safety profile of? Oxalamine for fetal health, considerably limiting the use of PEREBRON ® during pregnancy and in the subsequent period of breastfeeding.

However, strict medical supervision is required if PEREBRON ® is strictly necessary.

Interactions

Although no clinically relevant drug interactions are known, particular care should be taken with the intake of PEREBRON ® together with that of oral anticoagulants.